̽����ѡ

Oncternal Therapeutics Joins NextGenNK Competence Center 

On November 3 2021 Oncternal Therapeutics announced their entry to NextGenNK. “We look forward to strengthening our partnership with the world-renowned ̽����ѡ and joining other industry and academic partners in developing the next generation of cell therapies,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO. 

XNK Therapeutics Reports First Patient Included in Phase II Study in Multiple Myeloma

XNK Therapeutics AB (“XNK”) announced on July 1st 2021 that the first patient has been included in a Phase II clinical study to treat patients with Multiple myeloma using XNK’s leading autologous natural killer (NK) cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab). XNK and Sanofi are partners in NextGenNK.

Sorrento and KI researchers enter a collaborative agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer Cells

Sorrento Therapeutics, Inc. announced their entry into an additional collaborative agreement with research groups at ̽����ѡ, aimed at producing novel cell-based therapeutics using NK cells derived from induced pluripotent stem cells (“iPSCs”). Sorrento and KI are collaborative partners in NextGenNK.

XNK partners with KI on Phase II study in MM with support from Sanofi

XNK Therapeutics AB (“XNK”) announce their entry into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa (isatuximab). XNK and Sanofi are both collaborative partners within NextGenNK Competence Center.